1-2 of 2
Keywords: Cost-utility analysis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study

Subject Area:
Oncology
Michael P. Lux, Claudia Reichelt, Diethelm Wallwiener, Rolf Kreienberg, Walter Jonat, Michael Gnant, Matthias W. Beckmann, Falk C. Thiel
Journal: Onkologie
Onkologie (2010) 33 (7): 360–368.
https://doi.org/10.1159/000315699
Published Online: 22 June 2010
.... Zoledronic acid Breast cancer Bisphosphonate Cost-utility analysis Original Article · Originalarbeit Onkologie 2010;33:360 368 DOI: 10.1159/000315699 Published online: June 22, 2010 Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study...
View article titled, Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study
Open the PDF for Results of the Zometa® Cost-Utility Model for the German Healthcare System Based on the Results of the ABCSG-12 Study in another window
Journal Articles

Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System

Subject Area:
Oncology
Michael P. Lux, Achim Wöckel, Agnes Benedict, Stefan Buchholz, Noé;mi Kreif, Nadia Harbeck, Rolf Kreienberg, Manfred Kaufmann, Matthias W. Beckmann, Walter Jonat, Peyman Hadji, Wolfgang Distler, Guenther Raab, Hans Tesch, Georg Weyers, Kurt Possinger, Andreas Schneeweiss
Journal: Onkologie
Onkologie (2010) 33 (4): 155–166.
https://doi.org/10.1159/000286233
Published Online: 19 March 2010
.... Anastrozole Cost-effectiveness analysis Cost-utility analysis Incremental cost-effectiveness ratio Tamoxifen QALY Original Article · Originalarbeit Onkologie 2010;33:155 166 DOI: 10.1159/000286233 Published online: March 19, 2010 Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant...
View article titled, Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System
Open the PDF for Cost-Effectiveness Analysis of Anastrozole versus Tamoxifen in Adjuvant Therapy for Early-Stage Breast Cancer – A Health-Economic Analysis Based on the 100-Month Analysis of the ATAC Trial and the German Health System in another window